Literature DB >> 32991963

Identification of aberrantly expressed circular RNAs in hyperlipidemia-induced retinal vascular dysfunction in mice.

Ya-Nan Sun1, Ban Liu2, Jia-Jian Wang1, Xiu-Miao Li3, Jun-Ya Zhu3, Chang Liu4, Jin Yao4, Yu-Ling Zhong4, Qin Jiang5, Biao Yan6.   

Abstract

Hyperlipidemia-induced retinal vascular dysfunction is a complex pathological process. circRNAs are important regulators of biological processes and disease progression. However, the expression pattern of circRNAs in hyperlipidemia-induced retinal vascular dysfunction remains unclear. Herein, we used a murine model of hyperlipidemia and identified 317 differentially expressed circRNAs between hyperlipidemic retinas and normolipidemic retinas by circRNA microarrays. GO analysis indicated that the host genes of dysregulated circRNAs were targeted to cell differentiation (ontology: biological process), cytoplasm (ontology: cellular component), and protein binding (ontology: molecular function). Pathway analysis revealed that circRNAs-mediated network was mostly enriched in focal adhesion signaling. Notably, circLDB1 was significantly up-regulated in the serum of coronary artery disease patients and aqueous humor of age-related macular degeneration patients. circLDB1 regulated endothelial cell viability, proliferation, and apoptosis in vitro. Thus, circRNAs are the promising targets for the prediction and diagnosis of hyperlipidemia-induced vascular diseases.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Circular RNAs; GO analysis; Hyperlipidemia; KEGG pathway analysis

Mesh:

Substances:

Year:  2020        PMID: 32991963     DOI: 10.1016/j.ygeno.2020.09.055

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  1 in total

1.  Analysis of circRNA expression in chicken HD11 cells in response to avian pathogenic E.coli.

Authors:  Hongyan Sun; Yexin Yang; Yuyi Ma; Nayin Li; Jishuang Tan; Changhua Sun; Huan Li
Journal:  Front Vet Sci       Date:  2022-09-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.